

Gene Therapy Market: 2019-2026 - Market Analysis and Forecast

<https://marketpublishers.com/r/GBCD599E6295EN.html>

Date: November 2019

Pages: 255

Price: US\$ 1,999.00 (Single User License)

ID: GBCD599E6295EN

Abstracts

REPORT OVERVIEW:

Gene therapy has become one of the most rapidly growing and promising fields in regenerative medicine. As compared to conventional medicine, gene therapy is the single-dose solution for a wide application of diseases, significantly for genetic diseases, neurological, infectious and oncological disorders. Mainly encompasses the use of a viral vector to introduce an intact gene, either directly administered into the patient body (In-vivo) or indirectly via transduction of cells before infusion into the patient body (Ex-vivo), to reconstitute, remove, and modify a harmful gene variant.

The global gene therapy market was valued at \$1,049 million in 2018, and is estimated to reach \$10,443 million by 2026, registering a CAGR of 33.3% from 2018 to 2026.

Factors that drive the market growth involves, Increase in funding for R&D activities pertaining to gene therapy, For instance in 2018 cell and gene therapy companies raised over \$981 Million in venture financing, Moreover in 2018 M&A volume reached to \$18.8 Billion with a increase of 26% from 2017.

Increased in No. of Approved Products, By the end of Q3 2019 there are total 15 approved cell and gene therapy products, In 2017 FDA approves KYMRIA®[®], YESCARTA® and LUXTRNA®[®], In 2019 ZOLGENSMA®[®], ZYNTEGLO®[®] and COLLETEGENE®[®] get market approval in U.S., EU and Japan respectively.

Other factors that boost the market growth involves; increase in government support, ethical acceptance of gene therapy for cancer treatment, rise in prevalence of cancer and increase in awareness regarding the gene therapy.

However, high cost associated with the treatment (KYMRIAH® cost around \$475,000, and LUXTURN A® costs \$425,000 per Eye) and unwanted immune responses are expected to hamper the market growth.

The report also presents detailed quantitative analysis of the current market trends and future estimations from 2018 to 2026.

The forecasts cover 2 Vector Type with 13 Sub categories, 8 Gene Type , 6 Application Type, 4 Regions and 16 Countries.

The report comes with an associated file covering quantitative data from all numeric forecasts presented in the report.

KEY FINDINGS:

The report has the following key findings:

The global gene therapy market accounted for \$1,049 million in 2018 and is estimated to reach \$10,443 million by 2026, registering a CAGR of 33.3% from 2018 to 2026.

The viral vector segment was valued at \$566 million in 2018 and is estimated to reach \$5264 million by 2026, registering a CAGR of 32.1% from 2018 to 2026.

Non-viral vector segment exhibits the highest growth rate in the forecast.

Antigen was the largest contributor among the gene type segments.

The oncological disorders segment currently holds 63% of market share and is expected to continue its dominance in future, follows by the rare disease segment.

North America dominated the global gene therapy market in 2018 and is projected to continue its dominance in the future.

China is expected to grow the highest in the Asia-Pacific region during the forecast period.

TOPICS COVERED:

The report covers the following topics:

Market drivers, restraints and opportunities

Porter's Five Forces Analysis

Top Winning Strategies, Top Investment Pockets

Analysis of By Vector Type, Gene Type, and Application Type

CAR T-Cell Applications, Limitations, and Market & Industry Trends

50 Companies Profile, Product Portfolio, and Key Strategies

15 Approved Cell and Gene Therapy Product Profiles

30 gene therapy expected approvals in the phase III clinical trials

Gene Therapy clinical trials analysis from 1989 to 2018

Market analysis and forecasts from 2018 to 2026

FORECAST SEGMENTATION:

Market forecasts are provided for each of the following sub-markets and their categories:

1- By Vector Type

Viral vector

Adenoviruses

Lentiviruses

Adeno-Associated Virus

Retroviruses

Herpes Simplex Virus

Poxvirus

Vaccinia Virus

Others

Non-viral vector

Naked Plasmid Vectors

Electroporation

Gene Gun

Lipofection

Others

2- By Gene Type

Antigen

Cytokine

Tumor Suppressor

Suicide

Deficiency

Growth factors

Receptors

Others

3- By Application

Oncological Disorders

Rare Diseases

Cardiovascular Diseases

Neurological Disorders

Infectious disease

Other Diseases

4- By Region

North America: USA | Canada | Mexico

Europe: UK | Germany | France | Spain | Italy | Rest of Europe

Asia-Pacific: China | Japan | India | South Korea | Rest of Asia-Pacific

LAMEA: Brazil | South Africa | Rest of LAMEA

Contents

CHAPTER 1: INTRODUCTION

- 1.1 REPORT DESCRIPTION 17-18
- 1.2 TOPICS COVERED
- 1.3 KEY MARKET SEGMENTS
- 1.4 KEY BENEFITS
- 1.5 RESEARCH METHODOLOGY
- 1.6 TARGET AUDIENCE
- 1.7 COMPANIES MENTIONED 23-25

CHAPTER 2: EXECUTIVE SUMMARY

- 2.1 EXECUTIVE SUMMARY 26-28
- 2.2 CXO PROSPECTIVE

CHAPTER 3: MARKET OVERVIEW

- 3.1 MARKET DEFINITION AND SCOPE
- 3.2 KEY FINDINGS
- 3.3 TOP INVESTMENT POCKETS
- 3.4 TOP WINNING STRATEGIES
 - 3.4.1. Top winning strategies, by year, 2016-2018*
 - 3.4.2. Top winning strategies, by development, 2016-2018*(%)
 - 3.4.3. Top winning strategies, by company, 2016-2018*
- 3.5 TOP PLAYER POSITIONING, BY PIPELINE VOLUME, 2018
- 3.6 PORTERS FIVE FORCES ANALYSIS 37-38
- 3.7 MARKET DYNAMICS
 - 3.6.1 Drivers
 - 3.6.1.1 High investment for R&D activities pertaining to gene therapy
 - 3.6.1.2 Increase in prevalence of cancer
 - 3.6.1.3 Growth in awareness regarding gene therapy
 - 3.6.2 Restrains
 - 3.6.2.1 High cost associated with gene therapies
 - 3.6.2.2 Unwanted immune responses
 - 3.6.3 Opportunities
 - 3.6.3.1 Untapped potential for emerging markets

CHAPTER 4: GENE THERAPY APPROACH

4.1 OVERVIEW

4.2 IN VIVO APPROACH

4.3 EX VIVO APPROACH

CHAPTER 5: GENE THERAPY MARKET, BY VECTOR TYPE

5.1 OVERVIEW

5.1.1 Market size and forecast

5.2 VIRAL VECTORS

5.2.1 Key market trends

5.2.2 Key growth factors and opportunities

5.2.3 Market size and forecast 50-51

5.2.4 Market size and forecast by country

5.2.5 Adenovirus

5.2.6 Lentivirus

5.2.7 Adeno-Associated Virus

5.2.8 Retrovirus

5.2.9 Herpes Simplex Virus

5.2.10 Poxvirus

5.2.11 Vaccinia Virus

5.2.12 Others 59-60

5.3 NON-VIRAL VECTORS

5.3.1 Key market trends

5.3.2 Key growth factors and opportunities

5.3.3 Market size and forecast 62-63

5.3.4 Market size and forecast by country

5.3.5 Naked Plasmid Vector

5.3.6 Electroporation 66-67

5.3.7 Gene Gun

5.3.8 Lipofection 69-70

5.3.9 Others 71-72

CHAPTER 6: GENE THERAPY MARKET, BY GENE TYPE

6.1 OVERVIEW

6.1.1 Market size and forecast 73-74

6.2 ANTIGEN

- 6.2.1 Market size and forecast
- 6.2.2 Market size and forecast by country
- 6.3 CYTOKINE 77-78
 - 6.3.1 Market size and forecast
 - 6.3.2 Market size and forecast by country
- 6.4 TUMOR SUPPRESSOR 80-82
 - 6.4.1 Market size and forecast
 - 6.4.2 Market size and forecast by country
- 6.5 SUICIDE 84-85
 - 6.5.1 Market size and forecast
 - 6.5.2 Market size and forecast by country
- 6.6 DEFICIENCY
 - 6.6.1 Market size and forecast
 - 6.6.2 Market size and forecast by country
- 6.7 GROWTH FACTORS 89-91
 - 6.7.1 Market size and forecast
 - 6.7.2 Market size and forecast by country
- 6.8 RECEPTORS
 - 6.8.1 CAR T-Cell and Gene Therapy
 - 6.8.3.1 Introduction and Process
 - 6.8.3.2 Applications and Limitations 94-95
 - 6.8.3.3 Approved Products and Clinical Trials
 - 6.8.3.4 Market and Industry Trends
 - 6.8.2 Market size and forecast
 - 6.8.3 Market size and forecast by country
- 6.9 OTHERS
 - 6.9.1 Market size and forecast
 - 6.9.2 Market size and forecast by country

CHAPTER 7: GENE THERAPY MARKET, BY APPLICATION

- 7.1 OVERVIEW
 - 7.1.1 Market size and forecast
- 7.2 ONCOLOGICAL DISORDERS 106-108
 - 7.2.1 Market size and forecast
 - 7.2.2 Market size and forecast by country
- 7.3 RARE DISEASES 110-114
 - 7.3.1 Market size and forecast
 - 7.3.2 Market size and forecast by country

7.4 CARDIOVASCULAR DISEASES

7.4.1 Market size and forecast

7.4.2 Market size and forecast by country

7.5 NEUROLOGICAL DISORDERS

7.5.1 Market size and forecast

7.5.2 Market size and forecast by country

7.6 INFECTIOUS DISEASE

7.6.1 Market size and forecast

7.6.2 Market size and forecast by country

7.7 OTHER DISEASES

7.7.1 Market size and forecast

7.7.2 Market size and forecast by country

CHAPTER 8: GENE THERAPY MARKET, BY REGION

8.1 OVERVIEW

8.1.1 Market size and forecast

8.2 NORTH AMERICA

8.2.1 Key market trends

8.2.2 Key growth factors and opportunities

8.2.3 Market size and forecast, by country

8.2.4 Market size and forecast, by vector type

8.2.5 Market size and forecast, by gene type

8.2.6 Market size and forecast, by application

8.2.6.1 U.S. market size and forecast, by vector type

8.2.6.2 U.S. market size and forecast, by gene type

8.2.6.3 U.S. market size and forecast, by application

8.2.6.4 Canada market size and forecast, by vector type

8.2.6.5 Canada market size and forecast, by gene type

8.2.6.6 Canada market size and forecast, by application

8.2.6.7 Mexico market size and forecast, by vector type

8.2.6.8 Mexico market size and forecast, by gene type

8.2.6.9 Mexico market size and forecast, by application

8.3 EUROPE

8.4.1 Key market trends

8.4.2 Key growth factors and opportunities

8.4.3 Market size and forecast, by country

8.4.4 Market size and forecast, by vector type

8.4.5 Market size and forecast, by gene type

8.4.6 Market size and forecast, by application

8.3.6.1 Germany market size and forecast, by vector type

8.3.6.2 Germany market size and forecast, by gene type

8.3.6.3 Germany market size and forecast, by application

8.3.6.4 France market size and forecast, by vector type

8.3.6.5 France market size and forecast, by gene type

8.3.6.6 France market size and forecast, by application

8.3.6.7 UK market size and forecast, by vector type

8.3.6.8 UK market size and forecast, by gene type

8.3.6.9 UK market size and forecast, by application

8.3.6.10 Italy market size and forecast, by vector type

8.3.6.11 Italy market size and forecast, by gene type

8.3.6.12 Italy market size and forecast, by application

8.3.6.13 Spain market size and forecast, by vector type

8.3.6.14 Spain market size and forecast, by gene type

8.3.6.15 Spain market size and forecast, by application

8.3.6.16 Rest of Europe market size and forecast, by vector type

8.3.6.17 Rest of Europe market size and forecast, by gene type

8.3.6.18 Rest of Europe market size and forecast, by application

8.4 ASIA-PACIFIC

8.4.1 Key market trends

8.4.2 Key growth factors and opportunities

8.4.3 Market size and forecast, by country

8.4.4 Market size and forecast, by vector type

8.4.5 Market size and forecast, by gene type

8.4.6 Market size and forecast, by application

8.4.6.1 Japan market size and forecast, by vector type

8.4.6.2 Japan market size and forecast, by gene type

8.4.6.3 Japan market size and forecast, by application

8.4.6.4 China market size and forecast, by vector type

8.4.6.5 China market size and forecast by gene type

8.4.6.6 China market size and forecast, by application

8.4.6.7 India market size and forecast, by vector type

8.4.6.8 India market size and forecast, by gene type

8.4.6.9 India market size and forecast, by application

8.4.6.10 South Korea market size and forecast, by vector type

8.4.6.11 South Korea market size and forecast, by gene type

8.4.6.12 South Korea market size and forecast, by application

8.4.6.13 Rest of Asia-Pacific market size and forecast, by vector type

8.4.6.14 Rest of Asia-Pacific market size and forecast, by gene type

8.4.6.15 Rest of Asia-Pacific market size and forecast, by application

8.5 LAMEA

8.5.1 Key market trends

8.5.2 Key growth factors and opportunities

8.5.3 Market size and forecast, by country

8.5.4 Market size and forecast, by vector type

8.5.5 Market size and forecast, by gene type

8.5.6 Market size and forecast, by application

8.5.6.1 Brazil market size and forecast by vector type

8.5.6.2 Brazil market size and forecast, by gene type

8.5.6.3 Brazil market size and forecast, by application

8.5.6.4 South Africa market size and forecast, by vector type

8.5.6.5 South Africa market size and forecast, by gene type

8.5.6.6 South Africa market size and forecast, by application

8.5.6.7 Rest of LAMEA market size and forecast by vector type

8.5.6.8 Rest of LAMEA market size and forecast, by gene type

8.5.6.9 Rest of LAMEA market size and forecast, by application

CHAPTER 9: CLINICAL TRIALS ANALYSIS & PRODUCT PROFILES

9.1 OVERVIEW

9.2 CLINICAL TRIALS FROM 1989 TO 2018

9.2.1 Clinical Trials from 1989 to 2018: Based on Vector Type

9.2.2 Clinical Trials from 1989 to 2018: Based on Gene Type

9.2.3 Clinical Trials from 1989 to 2018: Based on Application

9.2.4 Clinical Trials from 1989 to 2018: Based on Region

9.3 CLINICAL TRIALS IN 2019

9.4 EXPECTED APPROVALS AND PIPELINE 177-178

9.5 APPROVED PRODUCTS PROFILES

9.5.1 GENDICINE

9.5.2 ONCORINE

9.5.3 REXIN-G

9.5.4 NEOVASCULGEN

9.5.5 GLYBERA

9.5.6 IMLYGIC

9.5.7 ZALMOXIS

9.5.8 STRIMVELIS

9.5.9 LUXTURN A

- 9.5.10 KYMRIA
- 9.5.11 YESCARTA
- 9.5.12 INVOSSA
- 9.5.13 ZOLGENSMA
- 9.5.14 ZYNTEGLO
- 9.5.15 COLLAGENE

CHAPTER 10: COMPANY PROFILES

10.1 KEY MARKET PLAYERS

- 10.1.1. Adaptimmune Therapeutics Plc 187-188
- 10.1.2. Abeona Therapeutics Inc. 189-190
- 10.1.3. Adverum Biotechnologies, Inc. 191-192
- 10.1.4. Applied Genetic Technologies Corporation 193-194
- 10.1.5. Arbutus Biopharma Corporation 195-196
- 10.1.6. Audentes Therapeutics Inc.
- 10.1.7. Avexis Inc.
- 10.1.8. Anchiano Therapeutics, Inc.
- 10.1.9. Bluebird Bio, Inc. 200-201
- 10.1.10. Celgene Corporation 202-203
- 10.1.11. CRISPR Therapeutics AG
- 10.1.12. Editas Medicine, Inc.
- 10.1.13. Gilead Sciences, Inc. (Kite Pharma, Inc.) 206-207
- 10.1.14. GlaxoSmithKline Plc 208-209
- 10.1.15. Intellia Therapeutics Inc.
- 10.1.16. Merck & Co., Inc. 211-212
- 10.1.17. Novartis AG 213-214
- 10.1.18. Regeneron, Inc. 215-216
- 10.1.19. Sangamo Therapeutics, Inc. 217-218
- 10.1.20. Spark Therapeutics, Inc. 219-220
- 10.1.21. Uniqure N.V. 221-222
- 10.1.22. Voyager Therapeutics, Inc. 223-224

10.2 OTHER COMPANY PROFILES

- 10.2.1. 4D Molecular Therapeutics
- 10.2.2. Advantagene, Inc.
- 10.2.3. Akouos, Inc.
- 10.2.4. Allogene Therapeutics, Inc.
- 10.2.5. Amgen, Inc.
- 10.2.6. American Gene Technologies International Inc.

- 10.2.7. Amicus Therapeutics, Inc.
- 10.2.8. Angas MG, Inc.
- 10.2.9. Arrowhead Pharmaceuticals, Inc.
- 10.2.10. Asklepios Biopharmaceutical, Inc.
- 10.2.11. AstraZeneca Plc
- 10.2.12. Atara Biotherapeutics, Inc.
- 10.2.13. Avrobio, Inc.
- 10.2.14. Bayer AG
- 10.2.15. Benitec Biopharma Limited
- 10.2.16. Biogen Inc.
- 10.2.17. Biomarin Pharmaceutical, Inc.
- 10.2.18. Bristol-Myers Squibb Company
- 10.2.19. Carsgen Therapeutics, Ltd
- 10.2.20. Casebia Therapeutics
- 10.2.21. Cellectis SA
- 10.2.22. Celyad SA
- 10.2.23. Curevac AG
- 10.2.24. Fibrocell Science Inc.
- 10.2.25. Freeline Therapeutics, Ltd.
- 10.2.26. Gensight Biologics S.A.
- 10.2.27. Intrexon Corporation
- 10.2.28. Oxford Biomedica Plc

CHAPTER 11: CONCLUSION & STRATEGIC RECOMMENDATIONS

11.1 STRATEGIC RECOMMENDATIONS 253-254

11.2 CONCLUSION

List Of Tables

LIST OF TABLES

TABLE NO.1 LIST OF MENTIONED ORGANIZATIONS AND COMPANIES

TABLE NO.2 GENE THERAPY MARKET SCOPE

TABLE NO.3 GLOBAL GENE THERAPY MARKET BY VECTOR TYPE 2018-2026
(\$MILLION)

TABLE NO.4 GLOBAL GENE THERAPY MARKET FOR VIRAL VECTORS, BY
REGION, 2018-2026 (\$MILLION)

TABLE NO.5 GLOBAL GENE THERAPY MARKET FOR VIRAL VECTORS, BY TYPE,
2018-2026 (\$MILLION)

TABLE NO.6 VIRAL VECTOR CHARACTERISTICS

TABLE NO.7 GLOBAL GENE THERAPY MARKET FOR NON VIRAL VECTORS, BY
REGION, 2018-2026 (\$MILLION)

TABLE NO.8 GLOBAL GENE THERAPY MARKET FOR NON VIRAL VECTORS, BY
TYPE, 2018-2026 (\$MILLION)

TABLE NO.9 OVERVIEW OF DIFFERENT NON-VIRAL VECTOR DELIVERY

TABLE NO.10 GLOBAL GENE THERAPY, BY GENE TYPE, 2018-2026 (\$MILLION)

TABLE NO.11 ANTIGEN GENE THERAPY MARKET, BY REGION, 2018-2026
(\$MILLION)

TABLE NO.12 CYTOKINES AS CANCER GENE THERAPY

TABLE NO.13 CYTOKINE GENE THERAPY MARKET, BY REGION, 2018-2026
(\$MILLION)

TABLE NO.14 TUMOR SUPPRESSOR BASED GENE THERAPY CANDIDATES

TABLE NO.15 TUMOR SUPPRESSOR GENES BY TYPES

TABLE NO.16 TUMOR SUPPRESSOR GENE THERAPY MARKET, BY REGION,
2018-2026 (\$MILLION)

TABLE NO.17 SUICIDE GENE THERAPY MARKET, BY REGION, 2018-2026
(\$MILLION)

TABLE NO.18 DEFICIENCY GENE THERAPY MARKET, BY REGION, 2018-2026
(\$MILLION)

TABLE NO.19 MAJOR GROWTH FACTOR FAMILIES, SOURCES AND ACTIONS

TABLE NO.20 GROWTH FACTORS GENE THERAPY MARKET, BY REGION,
2018-2026 (\$MILLION)

TABLE NO.21 RECEPTORS GENE THERAPY MARKET, BY REGION, 2018-2026
(\$MILLION)

TABLE NO.22 SUMMARY OF MAJOR ONCOLYTIC VIRUSES UNDER CLINICAL
DEVELOPMENT

TABLE NO.23 LIST OF FEW DNA REPLICATION INHIBITORS

TABLE NO.24 GENE THERAPY MARKET FOR OTHER GENE TYPE, BY REGION, 2018-2026 (\$MILLION)

TABLE NO.25 GLOBAL GENE THERAPY MARKET, BY APPLICATION, 2018-2026 (\$MILLION)

TABLE NO.26 LIST OF APPROVED GENE THERAPIES FOR CANCER

TABLE NO.27 LIST OF EXPECTED GENE THERAPY APPROVALS FOR CANCER INDICATIONS

TABLE NO.28 GENE THERAPY MARKET FOR ONCOLOGICAL DISORDERS, BY REGION, 2018-2026 (\$MILLION)

TABLE NO.29 LIST OF APPROVED GENE THERAPIES FOR RARE DISEASES

TABLE NO.30 LIST OF EXPECTED APPROVALS FOR RARE DISEASES INDICATIONS

TABLE NO.31 GENE THERAPY MARKET FOR RARE DISEASES, BY REGION, 2018-2026 (\$MILLION)

TABLE NO.32 LIST OF EXPECTED GENE THERAPY APPROVALS FOR CARDIOVASCULAR DISEASES INDICATIONS

TABLE NO.33 GENE THERAPY MARKET FOR CARDIOVASCULAR DISEASES, BY REGION, 2018-2026 (\$MILLION)

TABLE NO.34 LIST OF EXPECTED GENE THERAPY APPROVALS FOR NEUROLOGICAL DISORDERS INDICATIONS

TABLE NO.35 GENE THERAPY MARKET FOR NEUROLOGICAL DISORDERS, BY REGION, 2018-2026 (\$MILLION)

TABLE NO.36 GENE THERAPY MARKET FOR INFECTIOUS DISEASES, BY REGION, 2018-2026 (\$MILLION)

TABLE NO.37 LIST OF EXPECTED GENE THERAPY APPROVALS FOR DERMATOLOGICAL AND OPHTHALMOLOGICAL INDICATIONS

TABLE NO.38 GENE THERAPY MARKET FOR OTHER DISEASES, BY REGION, 2018-2026 (\$MILLION)

TABLE NO.39 GENE THERAPY MARKET, BY REGION, 2018-2026 (\$MILLION)

TABLE NO.40 NORTH AMERICA GENE THERAPY MARKET, BY COUNTRY, 2018-2026 (\$MILLION)

TABLE NO.41 NORTH AMERICA GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026 (\$MILLION)

TABLE NO.42 NORTH AMERICA GENE THERAPY MARKET, BY GENE TYPE, 2018-2026 (\$MILLION)

TABLE NO.43 NORTH AMERICA GENE THERAPY MARKET, BY APPLICATION, 2018-2026 (\$MILLION)

TABLE NO.44 U.S. GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026

(\$MILLION)

TABLE NO.45 U.S. GENE THERAPY MARKET, BY GENE TYPE, 2018-2026

(\$MILLION)

TABLE NO.46 U.S. GENE THERAPY MARKET, BY APPLICATION, 2018-2026

(\$MILLION)

TABLE NO.47 CANADA GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026

(\$MILLION)

TABLE NO.48 CANADA GENE THERAPY MARKET, BY GENE TYPE, 2018-2026

(\$MILLION)

TABLE NO.49 CANADA GENE THERAPY MARKET, BY APPLICATION, 2018-2026

(\$MILLION)

TABLE NO.50 MEXICO GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026

(\$MILLION)

TABLE NO.51 MEXICO GENE THERAPY MARKET, BY GENE TYPE, 2018-2026

(\$MILLION)

TABLE NO.52 MEXICO GENE THERAPY MARKET, BY APPLICATION, 2018-2026

(\$MILLION)

TABLE NO.53 EUROPE GENE THERAPY MARKET, BY COUNTRY, 2018-2026

(\$MILLION)

TABLE NO.54 EUROPE GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026

(\$MILLION)

TABLE NO.55 EUROPE GENE THERAPY MARKET, BY GENE TYPE, 2018-2026

(\$MILLION)

TABLE NO.56 EUROPE GENE THERAPY MARKET, BY APPLICATION, 2018-2026

(\$MILLION)

TABLE NO.57 GERMANY GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026

(\$MILLION)

TABLE NO.58 GERMANY GENE THERAPY MARKET, BY GENE TYPE, 2018-2026

(\$MILLION)

TABLE NO.59 GERMANY GENE THERAPY MARKET, BY APPLICATION, 2018-2026

(\$MILLION)

TABLE NO.60 FRANCE GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026

(\$MILLION)

TABLE NO.61 FRANCE GENE THERAPY MARKET, BY GENE TYPE, 2018-2026

(\$MILLION)

TABLE NO.62 FRANCE GENE THERAPY MARKET, BY APPLICATION, 2018-2026

(\$MILLION)

TABLE NO.63 UK GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026

(\$MILLION)

TABLE NO.64 UK GENE THERAPY MARKET, BY GENE TYPE, 2018-2026
(\$MILLION)

TABLE NO.65 UK GENE THERAPY MARKET, BY APPLICATION, 2018-2026
(\$MILLION)

TABLE NO.66 ITALY GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026
(\$MILLION)

TABLE NO.67 ITALY GENE THERAPY MARKET, BY GENE TYPE, 2018-2026
(\$MILLION)

TABLE NO.68 ITALY GENE THERAPY MARKET, BY APPLICATION, 2018-2026
(\$MILLION)

TABLE NO.69 SPAIN GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026
(\$MILLION)

TABLE NO.70 SPAIN GENE THERAPY MARKET, BY GENE TYPE, 2018-2026
(\$MILLION)

TABLE NO.71 SPAIN GENE THERAPY MARKET, BY APPLICATION, 2018-2026
(\$MILLION)

TABLE NO.72 REST OF EUROPE GENE THERAPY MARKET, BY VECTOR TYPE,
2018-2026 (\$MILLION)

TABLE NO.73 REST OF EUROPE GENE THERAPY MARKET, BY GENE TYPE,
2018-2026 (\$MILLION)

TABLE NO.74 REST OF EUROPE GENE THERAPY MARKET, BY APPLICATION,
2018-2026 (\$MILLION)

TABLE NO.75 ASIA-PACIFIC GENE THERAPY MARKET, BY COUNTRY, 2018-2026
(\$MILLION)

TABLE NO.76 ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR TYPE,
2018-2026 (\$MILLION)

TABLE NO.77 ASIA-PACIFIC GENE THERAPY MARKET, BY GENE TYPE, 2018-2026
(\$MILLION)

TABLE NO.78 ASIA-PACIFIC GENE THERAPY MARKET, BY APPLICATION,
2018-2026 (\$MILLION)

TABLE NO.79 JAPAN GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026
(\$MILLION)

TABLE NO.80 JAPAN GENE THERAPY MARKET, BY GENE TYPE, 2018-2026
(\$MILLION)

TABLE NO.81 JAPAN GENE THERAPY MARKET, BY APPLICATION, 2018-2026
(\$MILLION)

TABLE NO.82 CHINA GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026
(\$MILLION)

TABLE NO.83 CHINA GENE THERAPY MARKET, BY GENE TYPE, 2018-2026

(\$MILLION)

TABLE NO.84 CHINA GENE THERAPY MARKET, BY APPLICATION, 2018-2026

(\$MILLION)

TABLE NO.85 INDIA GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026

(\$MILLION)

TABLE NO.86 INDIA GENE THERAPY MARKET, BY GENE TYPE, 2018-2026

(\$MILLION)

TABLE NO.87 INDIA GENE THERAPY MARKET, BY APPLICATION, 2018-2026

(\$MILLION)

TABLE NO.88 SOUTH KOREA GENE THERAPY MARKET, BY VECTOR TYPE,
2018-2026 (\$MILLION)

TABLE NO.89 SOUTH KOREA GENE THERAPY MARKET, BY GENE TYPE,
2018-2026 (\$MILLION)

TABLE NO.90 SOUTH KOREA GENE THERAPY MARKET, BY APPLICATION,
2018-2026 (\$MILLION)

TABLE NO.91 REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY VECTOR
TYPE, 2018-2026 (\$MILLION)

TABLE NO.92 REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY GENE TYPE,
2018-2026 (\$MILLION)

TABLE NO.93 REST OF ASIA-PACIFIC GENE THERAPY MARKET, BY
APPLICATION, 2018-2026 (\$MILLION)

TABLE NO.94 LAMEA GENE THERAPY MARKET, BY COUNTRY, 2018-2026
(\$MILLION)

TABLE NO.95 LAMEA GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026
(\$MILLION)

TABLE NO.96 LAMEA GENE THERAPY MARKET, BY GENE TYPE, 2018-2026
(\$MILLION)

TABLE NO.97 LAMEA GENE THERAPY MARKET, BY APPLICATION, 2018-2026
(\$MILLION)

TABLE NO.98 BRAZIL GENE THERAPY MARKET, BY VECTOR TYPE, 2018-2026
(\$MILLION)

TABLE NO.99 BRAZIL THERAPY MARKET, BY GENE TYPE, 2018-2026 (\$MILLION)

TABLE NO.100 BRAZIL GENE THERAPY MARKET, BY APPLICATION, 2018-2026
(\$MILLION)

TABLE NO.101 SOUTH AFRICA GENE THERAPY MARKET, BY VECTOR TYPE,
2018-2026 (\$MILLION)

TABLE NO.102 SOUTH AFRICA THERAPY MARKET, BY GENE TYPE, 2018-2026
(\$MILLION)

TABLE NO.103 SOUTH AFRICA GENE THERAPY MARKET, BY APPLICATION,

2018-2026 (\$MILLION)

TABLE NO.104 REST OF LAMEA GENE THERAPY MARKET, BY VECTOR TYPE,
2018-2026 (\$MILLION)

TABLE NO.105 REST OF LAMEA THERAPY MARKET, BY GENE TYPE, 2018-2026
(\$MILLION)

TABLE NO.106 REST OF LAMEA GENE THERAPY MARKET, BY APPLICATION,
2018-2026 (\$MILLION)

TABLE NO.107 NUMBER OF CLINICAL TRIALS BASED ON VECTOR TYPE,
1989-2018

TABLE NO.108 NUMBER OF CLINICAL TRIALS BASED ON GENE TYPE, 1989-2018

TABLE NO.109 NUMBER OF CLINICAL TRIALS BASED ON APPLICATION,
1989-2018

TABLE NO.110 NUMBER OF CLINICAL TRIALS BASED ON REGION, 1989-2018

TABLE NO.111 BREAK DOWN OF 30, PHASE 3 CLINICAL TRIALS BASED ON
INDICATION AREA, Q2 2019

TABLE NO.112 LIST OF 30 PHASE 3, GENE THERAPY CANDIDATES IN CLINICAL
TRIALS, Q2 2019

TABLE NO.113 ADAPTIMMUNE THERAPEUTICS PLC.: COMPANY SNAPSHOT

TABLE NO.114 ADAPTIMMUNE THERAPEUTICS PLC.: BUSINESS UNIT

TABLE NO.115 ADAPTIMMUNE THERAPEUTICS PLC.: PRODUCT PORTFOLIO

TABLE NO.116 ABEONA THERAPEUTICS INC.: COMPANY SNAPSHOT

TABLE NO.117 ABEONA THERAPEUTICS INC.: PRODUCT CATEGORY

TABLE NO.118 ABEONA THERAPEUTICS INC.: PRODUCT PORTFOLIO

TABLE NO.119 ADVERUM BIOTECHNOLOGIES, INC.: COMPANY SNAPSHOT

TABLE NO.120 ADVERUM BIOTECHNOLOGIES, INC.: PRODUCT CATEGORY

TABLE NO.121 ADVERUM BIOTECHNOLOGIES, INC.: PRODUCT PORTFOLIO

TABLE NO.122 APPLIED GENETIC TECHNOLOGIES CORPORATION: COMPANY
SNAPSHOT

TABLE NO.123 APPLIED GENETIC TECHNOLOGIES CORPORATION: OPERATING
SEGMENTS

TABLE NO.124 APPLIED GENETIC TECHNOLOGIES CORPORATION: PRODUCT
PORTFOLIO

TABLE NO.125 ARBUTUS BIOPHARMA CORPORATION: COMPANY SNAPSHOT

TABLE NO.126 ARBUTUS BIOPHARMA CORPORATION: PRODUCT PORTFOLIO

TABLE NO.127 AUDENTES THERAPEUTICS INC.: COMPANY SNAPSHOT

TABLE NO.128 AUDENTES THERAPEUTICS INC.: PRODUCT PORTFOLIO

TABLE NO.129 AVEXIS INC.: COMPANY SNAPSHOT

TABLE NO.130 AVEXIS INC.: PRODUCT PORTFOLIO

TABLE NO.131 ANCHIANO THERAPEUTICS, INC.: COMPANY SNAPSHOT

TABLE NO.132 ANCHIANO THERAPEUTICS, INC.: PRODUCT CATEGORY
TABLE NO.133 ANCHIANO THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE NO.134 BLUEBIRD BIO, INC.: COMPANY SNAPSHOT
TABLE NO.135 BLUEBIRD BIO, INC.: PRODUCT CATEGORY
TABLE NO.136 BLUEBIRD BIO, INC.: PRODUCT PORTFOLIO
TABLE NO.137 CELGENE CORPORATION: COMPANY SNAPSHOT
TABLE NO.138 CELGENE CORPORATION: OPERATING SEGMENTS
TABLE NO.139 CELGENE CORPORATION: PRODUCT PORTFOLIO
TABLE NO.140 CRISPR THERAPEUTICS AG: COMPANY SNAPSHOT
TABLE NO.141 CRISPR THERAPEUTICS AG: PRODUCT PORTFOLIO
TABLE NO.142 EDITAS MEDICINE, INC.: COMPANY SNAPSHOT
TABLE NO.143 EDITAS MEDICINE, INC.: PRODUCT PORTFOLIO
TABLE NO.144 GILEAD SCIENCES. INC.: COMPANY SNAPSHOT
TABLE NO.145 GILEAD SCIENCES. INC.: OPERATING SEGMENTS
TABLE NO.146 GILEAD SCIENCES. INC.: PRODUCT PORTFOLIO
TABLE NO.147 GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE NO.148 GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
TABLE NO.149 GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE NO.150 INTELLIA THERAPEUTICS INC.: COMPANY SNAPSHOT
TABLE NO.151 INTELLIA THERAPEUTICS INC.: PRODUCT PORTFOLIO
TABLE NO.152 MERCK & CO.,INC.: COMPANY SNAPSHOT
TABLE NO.153 MERCK & CO.,INC.: OPERATING SEGMENTS
TABLE NO.154 MERCK & CO.,INC.: PRODUCT PORTFOLIO
TABLE NO.155 NOVARTIS AG: COMPANY SNAPSHOT
TABLE NO.156 NOVARTIS AG: OPERATING SEGMENTS
TABLE NO.157 NOVARTIS AG: PRODUCT PORTFOLIO
TABLE NO.158 REGENXBIO, INC.: COMPANY SNAPSHOT
TABLE NO.159 REGENXBIO, INC.: PRODUCT PORTFOLIO
TABLE NO.160 SANGAMO THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE NO.161 SANGAMO THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE NO.162 SANGAMO THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE NO.163 SPARK THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE NO.164 SPARK THERAPEUTICS, INC.: OPERATING SEGMENTS
TABLE NO.165 SPARK THERAPEUTICS, INC.: PRODUCT PORTFOLIO
TABLE NO.166 UNIQUE N.V.: COMPANY SNAPSHOT
TABLE NO.167 UNIQUE N.V.: OPERATING SEGMENTS
TABLE NO.168 UNIQUE N.V.: PRODUCT PORTFOLIO
TABLE NO.169 VOYAGER THERAPEUTICS, INC.: COMPANY SNAPSHOT
TABLE NO.170 VOYAGER THERAPEUTICS, INC.: OPERATING SEGMENTS

TABLE NO.171 VOYAGER THERAPEUTICS, INC.: PRODUCT PORTFOLIO

List Of Figures

LIST OF FIGURES

- FIGURE NO.1 GENE THERAPY MARKET SEGMENTS
- FIGURE NO.2 GENE THERAPY CLINICAL TRIALS AT THE END OF Q2 2019
- FIGURE NO.3 MERGERS AND ACQUISITIONS, BY VOLUME, 2016-2018*
- FIGURE NO.4 TOP INVESTMENT POCKETS: BY GENE TYPE, 2018
- FIGURE NO.5 BARGAINING POWER OF BUYERS
- FIGURE NO.6 BARGAINING POWER OF SUPPLIERS
- FIGURE NO.7 THREAT OF NEW ENTRANTS
- FIGURE NO.8 THREAT OF SUBSTITUTION
- FIGURE NO.9 COMPETITIVE RIVALRY
- FIGURE NO.10 RESTRAINTS AND DRIVERS: GLOBAL GENE THERAPY
- FIGURE NO.11 IN VIVO AND EX VIVO GENE THERAPY
- FIGURE NO.12 SYSTEMATIC AND TARGETED IN VIVO APPROACH
- FIGURE NO.13 EX-VIVO GENE THERAPY EXPLANATION
- FIGURE NO.14 EX-VIVO VS IN-VIVO GENE THERAPY: BREAKDOWN OF PIPELINE, 2018
- FIGURE NO.15 VIRAL VECTOR VS NON-VIRAL VECTOR: BREAKDOWN OF PIPELINE, 2018
- FIGURE NO.16 GLOBAL GENE THERAPY MARKET TREND BY VECTOR TYPE 2018-2026 (\$MILLION)
- FIGURE NO.17 BREAKDOWN OF MARKET SHARE OF VIRAL VECTORS ON THE BASIS OF TYPE
- FIGURE NO.18 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR VIRAL VECTORS, 2018 VS 2026 (%)
- FIGURE NO.19 ADENOVIRUS STRUCTURE
- FIGURE NO.20 RETROVIRUS VECTOR EDITING
- FIGURE NO.21 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR NON VIRAL VECTORS, 2018 VS 2026 (%)
- FIGURE NO.22 INOVIO'S ELECTROPORATION DEVICE CELECTRA
- FIGURE NO.23 MECHANISM OF PLASMID DNA DELIVERY BY CELLECTRA
- FIGURE NO.24 GLOBAL GENE THERAPY TREND, BY GENE TYPE, 2018-2026 (\$MILLION)
- FIGURE NO.25 COMPARATIVE REGIONAL SHARE ANALYSIS OF ANTIGEN GENE THERAPY MARKET, 2018 VS 2026 (%)
- FIGURE NO.26 COMPARATIVE REGIONAL SHARE ANALYSIS OF CYTOKINE GENE THERAPY MARKET, 2018 VS 2026 (%)

FIGURE NO.27 COMPARATIVE REGIONAL SHARE ANALYSIS OF TUMOR SUPPRESSOR GENE THERAPY MARKET, 2018 VS 2026 (%)

FIGURE NO.28 COMPARATIVE REGIONAL SHARE ANALYSIS OF SUICIDE GENE THERAPY MARKET, 2018 VS 2026 (%)

FIGURE NO.29 COMPARATIVE REGIONAL SHARE ANALYSIS OF DEFICIENCY GENE THERAPY MARKET, 2018 VS 2026 (%)

FIGURE NO.30 COMPARATIVE REGIONAL SHARE ANALYSIS OF GROWTH FACTORS GENE THERAPY MARKET, 2018 VS 2026 (%)

FIGURE NO.31 INTRACELLULAR CELL SIGNALING

FIGURE NO.32 CAR T-CELL PROCESS

FIGURE NO.33 SHARE OF CAR T-CELL TRIALS TARGETING CD19, 2018

FIGURE NO.34 GLOBAL CAR T-CELL THERAPY CLINICAL TRIALS, BY NUMBERS, 2007-2018

FIGURE NO.35 GLOBAL DISTRIBUTION OF CAR T-CELL THERAPEUTIC COMPANIES, 2018

FIGURE NO.36 COMPARATIVE REGIONAL SHARE ANALYSIS OF RECEPTORS GENE THERAPY MARKET, 2018 VS 2026 (%)

FIGURE NO.37 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR OTHER GENE TYPE, 2018 VS 2026 (%)

FIGURE NO.38 BREAK DOWN OF GENE THERAPY CLINICAL TRIALS, BY DISEASE INDICATION, 2018

FIGURE NO.39 NO. OF GENE THERAPY CLINICAL TRIALS, BY CANCER TYPES, 2018

FIGURE NO.40 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR ONCOLOGICAL DISORDERS, 2018 VS 2026

FIGURE NO.41 GENE THERAPY CLINICAL TRIALS BREAK DOWN, BY RARE DISEASES, 2018

FIGURE NO.42 BREAK DOWN OF RARE DISEASE CLINICAL TRIALS, BY DISEASE INDICATION, 2018

FIGURE NO.43 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR RARE DISEASES, 2018 VS 2026 (%)

FIGURE NO.44 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR CARDIOVASCULAR DISEASES, 2018 VS 2026 (%)

FIGURE NO.45 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR NEUROLOGICAL DISORDERS, 2018 VS 2026

FIGURE NO.46 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR INFECTIOUS DISEASES, 2018 VS 2026 (%)

FIGURE NO.47 COMPARATIVE REGIONAL SHARE ANALYSIS OF GENE THERAPY MARKET FOR OTHER DISEASES, 2018 VS 2026 (%)

FIGURE NO.48 GENE THERAPY CLINICAL TRIALS APPROVED WORLDWIDE FROM 1989-2018

FIGURE NO.49 COMPARISON OF VIRAL VS NON VIRAL CLINICAL TRIALS , 1989-2018

FIGURE NO.50 CLINICAL TRIALS BASED ON GENE TYPE, 1989-2018

FIGURE NO.51 CLINICAL TRIALS BASED ON APPLICATION, 1989-2018

FIGURE NO.52 CLINICAL TRIALS BASED ON REGION, 1989-2018

FIGURE NO.53 GENE THERAPY CLINICAL TRIALS AT THE END OF Q2 2019

FIGURE NO.54 ADAPTIMMUNE THERAPEUTICS PLC.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.55 ABEONA THERAPEUTICS INC.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.56 ADVERUM BIOTECHNOLOGIES, INC.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.57 AGTC: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.58 ARBUTUS BIOPHARMA CORPORATION.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.59 BLUEBIRD BIO, INC.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.60 CELGENE CORPORATION: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.61 GILEAD SCIENCES. INC.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.62 GILEAD SCIENCES. INC.: REVENUE, BY GEOGRAPHY 2018 (%)

FIGURE NO.63 GSK PLC: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.64 GSK PLC: REVENUE BY GEOGRAPHY AND PRODUCT SEGMENT 2018 (%)

FIGURE NO.65 MERCK & CO.,INC.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.66 MERCK & CO.,INC.:REVENUE BY GEOGRAPHY & PRODUCT SEGMENT 2018(%)

FIGURE NO.67 NOVARTIS AG: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.68 NOVARTIS AG: REVENUE BY GEOGRAPHY AND PRODUCT SEGMENT 2018 (%)

FIGURE NO.69 REGENXBIO, INC.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.70 SANGAMO THERAPEUTICS, INC.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.71 SPARK THERAPEUTICS, INC.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.72 UNIQUE N.V.: REVENUE, 2016-2018 (\$MILLION)

FIGURE NO.73 VOYAGER THERAPEUTICS, INC.: REVENUE, 2016-2018 (\$MILLION)

I would like to order

Product name: Gene Therapy Market: 2019-2026 - Market Analysis and Forecast

Product link: <https://marketpublishers.com/r/GBCD599E6295EN.html>

Price: US\$ 1,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GBCD599E6295EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970